do glp 1 agonists cause pancreatic cancer Risk of associated with GLP-1 receptor agonist therapy Is there a correlation between
Description
S2CID 40330443
Both of these innovations are on the market already
When one drug inhibits CYP enzymes responsible for metabolising another CNS drug, plasma and brain concentrations may rise, increasing the risk of toxicity
the liver cells mitochondria are particularly vulnerable to damage
Preliminary results indicate that such drugs might not only be effective for obesity and diabetes but also for a number of other diseases including osteoarthritis, Parkinson's disease and a range of conditions caused by a buildup of fat in the liver, known as nonalcoholic steatohepatitis (NASH) (Brandt, Mller, DiMarchi)
